Pharmacoeconomic analysis of telavancin use in russian healthcare system for treatment of patients with complicated skin and soft tissue infections
It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with complicated skin and soft tissue infections was held. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes more economic sense in terms of cost-efficacy ratio than daptomycin, tigecycline and linezolid. Telavancin use is more advantageous in terms of budget impact analysis as compared to linezolid and daptomycin use: saving up to 32,705,178 rubles from the budget, which enables to treat up to 126 more patients.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link: Kolbin A.S., Vilyum I.A., Proscurin M.A., Balikina Yu.Ye. Pharmacoeconomic analysis of telavancin use in russian healthcare system for treatment of patients with complicated skin and soft tissue infections // Pharmacoeconomics: theory and practice. - 2016. - Vol.4, №2. - P.82-87 DOI: https://doi.org/10.30809/phe.2.2016.2